On February 8, 2021, Kimon
Angelides (“Mr. Angelides”) resigned as a member of the Board of Directors (the “Board”) of Petra Acquisition,
Inc. (the “Company”). To fill the vacancy on the Audit Committee of the Board (the “Committee”) created
by Mr. Angelides’ resignation, the Board appointed Anthony Hayes, a current independent Board member, to serve as a member
of the Committee.
Effective February 22, 2021, the corporate
governance and nominating committee recommended, and the board of directors approved, the appointment of William H. Carson to fill
the vacancy resulting from the resignation of Mr. Angelides. The Board determined that Mr. Carson qualifies as independent under
the director independence standards set forth i n the rules and regulations of the Securities and Exchange Commission and applicable
NASDAQ listing standards.
There is no arrangement or understanding between Mr. Carson and
any other persons pursuant to which Mr. Carson was selected as a director, and there are no related party transactions involving
Mr. Carson that are reportable under Item 404(a) of Regulation S-K. Mr. Carson will receive ten thousand (10,000) shares of the
Company’s common stock from the Company’s Sponsor, Petra Investment Holdings, LLC, as compensation for his service
on the Board.
Below is a description of Mr. Carson’s professional
William H. Carson
73, of Texas, is a forty year management veteran in the prescription and OTC drug industries with broad exposure to product licensing,
new product R&D, manufacturing, Rx-to-OTC switches, company acquisition and new business entity development. He has held Leadership
roles at Novartis, Bayer, Galderma, in MTO (Plant Management, New Facility Construction, Compliance), Product Development and Regulatory
Affairs (NDA, ANDA, RX to OTC Switch, OTC Monographs), and LMA (Due Diligence, Organizational Review, Post Merger/Acquisition Integration).
For the past 9 years,
Carson has operated his own consulting business taking on consulting assignments in: compliance, production, licensing and acquisition
product development and FDA/regulatory strategy. Carson started his career with Dorsey Laboratories Division, Sandoz Pharmaceuticals
where he remained employed from 1972-1994 ; he served in a variety of director roles such as Director of Regulatory Affairs, and
Director of New Products. He last served as Vice President of Scientific Affairs, managing the the FDA approval process for the
switches of Tavist-1 and Tavist-D from Rx to OTC status. From 1994-1996, he served as Senior Vice President of OTC Products at
Goldline Pharmaecuticals. From 1996-2004 he was Vice President, Scientific Affairs with Bayer Consumer Care Division (NYSE: BAYRY).
From 1996- 2004 he served as Senior Vice-President, Medical &Regulatory Affairs at Galderma Laboratories, a skin health pharma
company. There he built departments to support a period of rapid sales growth, new product approvals and acquisitions. He also
was the team leader for the integration of two major acquisitions, Collagenix in the U.S. and Q-Med in Europe.
Mr. Carson has a BS and MS from University
of Nebraska in Physiology and Biochemistry
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: March 5, 2021
PETRA ACQUISITION, INC.
/s/ Andreas Typaldos
Chairman & Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
Amendments to Articles of Incorporation or - Oct. 13, 2021
Lawrence M. Feis just provided an update on share ownership of Petra Acquisition Inc. - Oct. 12, 2021
Paul J. Glazer just provided an update on share ownership of Petra Acquisition Inc. - Oct. 12, 2021
Prospectuses and communications, business combinations - Oct. 4, 2021
Lawrence M. Feis just provided an update on share ownership of Petra Acquisition Inc. - Sept. 28, 2021